Sign in
WithdrawnPhase 1/2

Immunomodulation Using VB-201 to Reduce Arterial Inflammation in Treated HIV - VITAL HIV Trial

Key facts

Who runs it
Priscilla Hsue, MD
Where
San Francisco, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 1/2
Started
1 Jul 2022
Expected to end
1 Jul 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • VB-201
  • Placebo
Record updated
15 September 2022
Why it stopped
Funding for this trial has not been established.

Who can take part

Age
40 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Documented HIV infection
  • On continuous antiretroviral therapy and virologically suppressed HIV infection for ≥12 weeks prior to study entry
  • CD4 T-cell count > 350 cells/mm3
  • Male or female between the ages ≥ 40 years of age to <≤75
  • Documented cardiovascular disease (1. Prior myocardial infarction, 2. History of percutaneous coronary intervention, 3. History of coronary artery bypass graft OR 4. Angiographic evidence of >50% stenosis in at least one coronary artery] OR 1 CVD risk factor (T2DM, current smoking, hypertension, dyslipidemia, hsCRP≥2mg/L, family history)
  • TBR of >1.6 of the MDS of the carotid/aorta at baseline. This baseline arterial TBR cutoff excludes the rare individual that lacks appreciable arterial inflammation. It is notable that while 5-10% of uninfected individuals will have lower TBRs, it is rare that an HIV infected individual will fall below this range
  • Female subjects must either be of non-childbearing potential as defined by menopause with amenorrhea for >2 years, bilateral oophorectomy, or agree to use adequate contraception throughout the study and for at least one month following termination and have a negative pregnancy test at screening prior to the first dose of drug
  • Males must use at least one method of contraception throughout the study

Who cannot take part

  • Evidence of tuberculosis infection at screening within 30 days prior to screening
  • On additional immunosuppressant or immunomodulatory therapies
  • Uncontrolled hypertension or diabetes requiring insulin
  • Cancer within the last 5 years with exception of squamous cell carcinoma and basal cell carcinoma
  • Acute systemic infection within 30 days
  • AST/ALT or alkaline phosphatase >2x ULN
  • Nephrotic syndrome or eGFR <60 mL/min/1.73m2
  • Cytopenias which include 1) WBC <3.5 x103/uL 2) Platelet <120 x103/uL 3) ANC <1.5 x103/uL, and absolute lymphocytes <0.8 x 103/uL
  • Anemia as fined by <10 g/dL
  • Family history of long QT syndrome, using medication that prolongs QT internal, OR evidence of prolonged QT of >470 msec as evidenced by ECG
  • Pregnant/nursing women

Where in United States

  • Zuckerberg San Francisco General HospitalSan Francisco, United States

About the trial

What the trial wants to find out

This study is a double blinded, placebo-controlled, randomized, parallel group study, designed to compare the efficacy and safety of VB-201 80mg taken orally once daily to placebo for anti-inflammation in HIV-infected subjects.

The 2 groups in the trial

  • VB-201Treatment being tested

    One dose of VB-201 80 mg (1 tablet) will be administered orally once daily for 52 weeks.

  • PlaceboPlacebo, for comparison

    One dose of placebo 80 mg (1 tablet) will be administered orally once daily for 52 weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
15 September 2022